SRSF2 and myelodysplastic syndrome: In 5/17 (29%) cases the SF3B1 VAF was lower than the VAF of additional spliceosome mutations (SRSF2: n = 2, all MDS-EB-1; ZRSR2: n = 3, all SF3B1ent; Supplementary Fig. S8).